Market revenue in 2023 | USD 75.2 million |
Market revenue in 2030 | USD 176.2 million |
Growth rate | 12.9% (CAGR from 2023 to 2030) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 60.11% in 2023. Horizon Databook has segmented the Canada head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Canada is anticipated to witness exponential growth opportunities owing to the increased disease burden of head and neck cancer and rising awareness of therapeutics among the population. According to the Canadian Cancer Society, in 2023, about 7,900 new head and neck cancer cases were estimated to be diagnosed in 2023, with nearly 2,100 related deaths.
Recent drug approvals for head and neck cancer in Canada are expected to support the country’s market. For instance, in October 2020, Merck received approval from Health Canada for its KEYTRUDA (pembrolizumab) drug for treating metastatic or unresectable recurrent head and neck cancer.
Health Canada also approved KEYTRUDA in combination with platinum and Fluorouracil (FU) chemotherapy as the first-line treatment of metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).
Horizon Databook provides a detailed overview of country-level data and insights on the Canada head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Canada head and neck cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account